Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antimycobacterial agents

W W Yew1, C H Chau

  • 1Tuberculosis & Chest Unit, Grantham Hospital, Hong Kong.

Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace
|October 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Grave impact of undetected rpoB I572F mutation on clinical course of multidrug-resistant tuberculosis: a case report.

Hong Kong medical journal = Xianggang yi xue za zhi·2023
Same author

Role of oxidative stress in clofazimine-induced cardiac dysfunction in a zebrafish model.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2020
Same author

Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2018
Same author

Delayed diagnosis of tuberculosis: risk factors and effect on mortality among older adults in Hong Kong.

Hong Kong medical journal = Xianggang yi xue za zhi·2018
Same author

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2016
Same author

Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.

Hong Kong medical journal = Xianggang yi xue za zhi·2015
Same journal

Preventable yet persistent: silicosis and gaps in public health policy - a narrative review.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2026
Same journal

Takotsubo syndrome due to occupational stress in a physician.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2026
Same journal

Spirometry after treatment completion for pulmonary tuberculosis - a necessity?

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2026
Same journal

Heart failure at the crossroads of climate change and environmental health: emerging risks, mechanistic insights, and future directions.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2026
Same journal

Aspiration pneumonia in stroke survivors: prevalence and clinical associations at Bolan Medical Complex.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2026
Same journal

The silent fractures: unmasking osteoporosis in south Indian chronic obstructive pulmonary disease patients.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2026
See all related articles

New antimycobacterial agents are needed for tuberculosis and atypical mycobacterial infections. Fluoroquinolones, macrolides, rifamycins, carbapenems, and other agents show promise but require further clinical evaluation.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Resurgent tuberculosis and increased atypical mycobacterial infections in immunocompromised individuals necessitate novel antimycobacterial agents.
  • Existing treatments face challenges, particularly with multidrug-resistant tuberculosis (MDR-TB) and infections caused by non-tuberculous mycobacteria.

Purpose of the Study:

  • To review and evaluate the potential of various novel and existing antimicrobial agents against tuberculosis and atypical mycobacterial infections.
  • To identify promising therapeutic options for drug-susceptible, multidrug-resistant tuberculosis, and infections caused by Mycobacterium fortuitum, Mycobacterium avium-intracellulare, and Mycobacterium chelonae.

Main Methods:

  • Literature review and analysis of existing data on antimycobacterial agents.

Related Experiment Videos

  • Assessment of in vitro and clinical evidence for fluoroquinolones, macrolides, rifamycins, carbapenems, and other drug classes.

    • Main Results:

    • Fluoroquinolones (ofloxacin, ciprofloxacin) show promise for MDR-TB and M. fortuitum infections.
    • Clarithromycin is active against M. avium-intracellulare, M. fortuitum, and M. chelonae.
    • Rifabutin is effective for drug-susceptible TB and potentially for disseminated M. avium-intracellulare infections, and as prophylaxis.
    • Imipenem may treat M. fortuitum and M. chelonae infections.
    • Clofazimine and aminosidine warrant further evaluation for MDR-TB and M. avium-intracellulare.

    Conclusions:

    • Several agents, including fluoroquinolones, clarithromycin, rifabutin, imipenem, clofazimine, and aminosidine, demonstrate potential for treating challenging mycobacterial infections.
    • Broader clinical evaluation of these agents is essential to establish their definitive roles in patient care.